Complex Cases of Social Anxiety Disorder (SAD)

  • Akiko Kawaguchi
  • Norio Watanabe


Social anxiety disorder (SAD) is a highly prevalent and chronic psychiatric disorder. Several kinds of co-occurring psychiatric problems are frequently observed in SAD. Selective serotonin reuptake inhibitors (SSRIs) or cognitive behavioral therapy (CBT), which have been showed useful for SAD, should be selected with taking account of possible comorbidities. Furthermore, attention should be paid to comorbid neurodevelopmental disorders in those with SAD.

In this article, we summarized current findings of how to diagnose or discriminate those comorbidities and treatment suggestions according to each condition. Useful interventions for those complicated cases of SAD are still developing, and continuing exploring is expected.


Social anxiety disorder Depression Autism spectrum disorder Attention deficit hyperactivity disorder 


Disclosure Statement

“The authors have nothing to disclose.”


  1. 1.
    Clark D, Wells A. A cognitive model of social phobia. In: Heimberg RG, Liebowitz M, Hope DA, Schneier FR, editors. Social phobia: diagnosis, assessment and treatment. Guilford press, New York. 1995.Google Scholar
  2. 2.
    Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368–76.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169–84.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Weissman MM, Bland RC, Canino GJ, Greenwald S, Lee CK, Newman SC, et al. The cross-national epidemiology of social phobia: a preliminary report. Int Clin Psychopharmacol. 1996;11(Suppl 3):9–14.CrossRefPubMedGoogle Scholar
  5. 5.
    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):593–602.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Keller MB. The lifelong course of social anxiety disorder: a clinical perspective. Acta Psychiatr Scand Suppl. 2003;417:85–94.CrossRefGoogle Scholar
  7. 7.
    Katzelnick DJ, Kobak KA, DeLeire T, Henk HJ, Greist JH, Davidson JR, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158(12):1999–2007.CrossRefPubMedGoogle Scholar
  8. 8.
    Stein MB, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Pyne JM, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care. 2005;43(12):1164–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Bas-Hoogendam JM, Blackford JU, Bruhl AB, Blair KS, van der Wee NJ, Westenberg PM. Neurobiological candidate endophenotypes of social anxiety disorder. Neurosci Biobehav Rev. 2016;71:362–78.CrossRefPubMedGoogle Scholar
  10. 10.
    Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. A J Psychiatry. 2007;164(10):1476–88.CrossRefGoogle Scholar
  11. 11.
    Hattingh CJ, Ipser J, Tromp SA, Syal S, Lochner C, Brooks SJ, et al. Functional magnetic resonance imaging during emotion recognition in social anxiety disorder: an activation likelihood meta-analysis. Front Hum Neurosci. 2012;6:347.PubMedGoogle Scholar
  12. 12.
    Irle E, Ruhleder M, Lange C, Seidler-Brandler U, Salzer S, Dechent P, et al. Reduced amygdalar and hippocampal size in adults with generalized social phobia. J Psychiatry Neurosci. 2010;35(2):126–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Liao W, Xu Q, Mantini D, Ding J, Machado-de-Sousa JP, Hallak JE, et al. Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. Brain Res. 2011;1388:167–77.CrossRefPubMedGoogle Scholar
  14. 14.
    Meng Y, Lui S, Qiu C, Qiu L, Lama S, Huang X, et al. Neuroanatomical deficits in drug-naive adult patients with generalized social anxiety disorder: a voxel-based morphometry study. Psychiatry Res. 2013;214(1):9–15.CrossRefPubMedGoogle Scholar
  15. 15.
    Morey RA, Gold AL, LaBar KS, Beall SK, Brown VM, Haswell CC, et al. Amygdala volume changes in posttraumatic stress disorder in a large case-controlled veterans group. Arch Gen Psychiatry. 2012;69(11):1169–78.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hayano F, Nakamura M, Asami T, Uehara K, Yoshida T, Roppongi T, et al. Smaller amygdala is associated with anxiety in patients with panic disorder. Psychiatry Clin Neurosci. 2009;63(3):266–76.CrossRefPubMedGoogle Scholar
  17. 17.
    Kawaguchi A, Nemoto K, Nakaaki S, Kawaguchi T, Kan H, Arai N, et al. Insular volume reduction in patients with social anxiety disorder. Front Psych. 2016;7:3.Google Scholar
  18. 18.
    Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther. 1998;36(4):455–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Schneier FR. Clinical practice. Social anxiety disorder. N Engl J Med. 2006;355(10):1029–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Gross R, Olfson M, Gameroff MJ, Shea S, Feder A, Lantigua R, et al. Social anxiety disorder in primary care. Gen Hosp Psychiatry. 2005;27(3):161–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62(2):190–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(7):785–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002;63(2):152–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156(5):756–60.PubMedGoogle Scholar
  26. 26.
    Blanco C, Schneier FR, Schmidt A, Blanco-Jerez CR, Marshall RD, Sanchez-Lacay A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia. Comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry. 1992;49(4):282–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332–9.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety. 1999;10(3):89–98.CrossRefPubMedGoogle Scholar
  30. 30.
    Kawaguchi A, Watanabe N, Nakano Y, Ogawa S, Suzuki M, Kondo M, et al. Group cognitive behavioral therapy for patients with generalized social anxiety disorder in Japan: outcomes at 1-year follow up and outcome predictors. Neuropsychiatr Dis Treat. 2013;9:267–75.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Andrews G, Creamer M, Crino R, Hunt C, Lampe L, Page A. The treatment of anxiety disorders clinician guides and patient manuals. Cambridge University Press, Cambridge. 2002.Google Scholar
  32. 32.
    Gould RA, Buckminster S, Pollack MH, Otto MW, Massachusetts LY. Cognitive-behavioral and pharmacological treatment for social phobia:a meta-analysis. Clin Psychol Sci Pract. 1997;4(4):291–306.CrossRefGoogle Scholar
  33. 33.
    Kuusikko S, Pollock-Wurman R, Jussila K, Carter AS, Mattila ML, Ebeling H, et al. Social anxiety in high-functioning children and adolescents with autism and asperger syndrome. J Autism Dev Disord. 2008;38(9):1697–709.CrossRefPubMedGoogle Scholar
  34. 34.
    Bellini S. Social skill deficits and anxiety in high-functioning adolescents with autism spectrum disorders. Focus Autism Other Dev Disabl. 2004;19(2):78–86.CrossRefGoogle Scholar
  35. 35.
    Lugnegard T, Hallerback MU, Gillberg C. Psychiatric comorbidity in young adults with a clinical diagnosis of Asperger syndrome. Res Dev Disabil. 2011;32(5):1910–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Bejerot S, Eriksson JM, Mortberg E. Social anxiety in adult autism spectrum disorder. Psychiatry Res. 2014;220(1–2):705–7.CrossRefPubMedGoogle Scholar
  37. 37.
    White SW, Kreiser NL, Pugliese C, Scarpa A. Social anxiety mediates the effect of autism spectrum disorder characteristics on hostility in young adults. Autism : Int J Res Pract. 2012;16(5):453–64.CrossRefGoogle Scholar
  38. 38.
    White SW, Albano AM, Johnson CR, Kasari C, Ollendick T, Klin A, et al. Development of a cognitive-behavioral intervention program to treat anxiety and social deficits in teens with high-functioning autism. Clin Child Fam Psychol Rev. 2010;13(1):77–90.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Cath DC, Ran N, Smit JH, van Balkom AJ, Comijs HC. Symptom overlap between autism spectrum disorder, generalized social anxiety disorder and obsessive-compulsive disorder in adults: a preliminary case-controlled study. Psychopathology. 2008;41(2):101–10.CrossRefPubMedGoogle Scholar
  40. 40.
    Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord. 1989;19(2):185–212.CrossRefPubMedGoogle Scholar
  41. 41.
    Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659–85.CrossRefGoogle Scholar
  42. 42.
    Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001;31(1):5–17.CrossRefPubMedGoogle Scholar
  43. 43.
    Ashwood KL, Gillan N, Horder J, Hayward H, Woodhouse E, McEwen FS, et al. Predicting the diagnosis of autism in adults using the Autism-Spectrum Quotient (AQ) questionnaire. Psychol Med. 2016;46(12):2595–604.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Freeth M, Bullock T, Milne E. The distribution of and relationship between autistic traits and social anxiety in a UK student population. Autism : Int J Res Pract. 2013;17(5):571–81.CrossRefGoogle Scholar
  45. 45.
    Eriksson JM, Andersen LM, Bejerot S. RAADS-14 screen: validity of a screening tool for autism spectrum disorder in an adult psychiatric population. Molecular Autism. 2013;4(1):49.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kreiser NL, White SW. Measuring social anxiety in adolescents and adults with high functioning autism: the development of a screening instrument. In: Kreiser NL, Pugliese C, editors. Co-occurring psychological and behavioral problems in adolescents and adults with features of autism spectrum disorder: assessment and characteristics. Toronto: Symposium conducted at the meeting of the Association for Behavioral and Cognitive Therapies; 2011.Google Scholar
  47. 47.
    Kreiser NL, White SW. Assessment of social anxiety in children and adolescents with autism spectrum disorder. Clin Psychol Sci Pract. 2014;21:18–31.CrossRefGoogle Scholar
  48. 48.
    White SW, Ollendick T, Scahill L, Oswald D, Albano AM. Preliminary efficacy of a cognitive-behavioral treatment program for anxious youth with autism spectrum disorders. J Autism Dev Disord. 2009;39(12):1652–62.CrossRefPubMedGoogle Scholar
  49. 49.
    Wood JJ, Ehrenreich-May J, Alessandri M, Fujii C, Renno P, Laugeson E, et al. Cognitive behavioral therapy for early adolescents with autism spectrum disorders and clinical anxiety: a randomized, controlled trial. Behav Ther. 2015;46(1):7–19.CrossRefPubMedGoogle Scholar
  50. 50.
    Wood JJ, Drahota A, Sze K, Har K, Chiu A, Langer DA. Cognitive behavioral therapy for anxiety in children with autism spectrum disorders: a randomized, controlled trial. J Child Psychol Psychiatry. 2009;50(3):224–34.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kuroda M, Kawakubo Y, Kuwabara H, Yokoyama K, Kano Y, Kamio YA. Cognitive-behavioral intervention for emotion regulation in adults with high-functioning autism spectrum disorders: study protocol for a randomized controlled trial. Trials. 2013;14:231.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Koyuncu A, Ertekin E, Yuksel C, Aslantas Ertekin B, Celebi F, Binbay Z, et al. Predominantly inattentive type of ADHD is associated with social anxiety disorder. J Atten Disord. 2015;19(10):856–64.CrossRefPubMedGoogle Scholar
  54. 54.
    Conners DE, Sparrow MA. Conners’ Adult ADHD Rating Scales (CAARS). New York: Multihealth Systems, Inc.; 1999.Google Scholar
  55. 55.
    Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35(2):245–56.CrossRefPubMedGoogle Scholar
  56. 56.
    Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1088–96.Google Scholar
  57. 57.
    Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212–21.CrossRefPubMedGoogle Scholar
  58. 58.
    Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol. 2009;29(6):561–4.CrossRefPubMedGoogle Scholar
  59. 59.
    Choy Y, Schneier FR, Heimberg RG, KS O, Liebowitz MR. Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress Anxiety. 2008;25(3):230–40.CrossRefPubMedGoogle Scholar
  60. 60.
    Heimberg RG, Makris GS, Juster HR, Ost LG, Rapee RM. Social phobia: a preliminary cross-national comparison. Depress Anxiety. 1997;5(3):130–3.CrossRefPubMedGoogle Scholar
  61. 61.
    Kleinknecht RA, Dinnel DL, Kleinknecht EE, Hiruma N, Harada N. Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin kyofusho. J Anxiety Disord. 1997;11(2):157–77.CrossRefPubMedGoogle Scholar
  62. 62.
    Wu H, Yu D, He Y, Wang J, Xiao Z, Li C. Morita therapy for anxiety disorders in adults. Cochrane Database Syst Rev. 2015(2):CD008619.Google Scholar
  63. 63.
    Clarvit SR, Schneier FR, Liebowitz MR. The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. J Clin Psychiatry. 1996;57(11):523–7.CrossRefPubMedGoogle Scholar
  64. 64.
    Chang SC. Social anxiety (phobia) and east Asian culture. Depress Anxiety. 1997;5(3):115–20.CrossRefPubMedGoogle Scholar
  65. 65.
    Kim J, Rapee RM, Gaston JE. Symptoms of offensive type Taijin-Kyofusho among Australian social phobics. Depress Anxiety. 2008;25(7):601–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors? Int J Neuropsychopharmacol. 2001;4(3):231–7.CrossRefPubMedGoogle Scholar
  67. 67.
    Nagata T, van Vliet I, Yamada H, Kataoka K, Iketani T, Kiriike N. An open trial of paroxetine for the “offensive subtype” of Taijin kyofusho and social anxiety disorder. Depress Anxiety. 2006;23(3):168–74.CrossRefPubMedGoogle Scholar
  68. 68.
    Nagata T, Wada A, Yamada H, Iketani T, Kiriike O. Effect of milnacipran on insight and stress coping strategy in patients with Taijin Kyofusho. Int J Psychiatry Clin Pract. 2005;9(3):193–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Akiko Kawaguchi
    • 1
  • Norio Watanabe
    • 2
  1. 1.Department of Psychiatry and Cognitive-Behavioral MedicineNagoya City University Graduate School of Medical SciencesNagoyaJapan
  2. 2.Department of Health Promotion and Human Behavior, Department of Clinical EpidemiologyGraduate School of Public Health, Kyoto UniversityKyotoJapan

Personalised recommendations